Sanj K. Patel - 01 May 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Reporting relationship: CHAIRMAN & CEO, Director
Issuer ticker: KNSA
Reported as of: 01 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2025, 16:49:13 UTC
Prior SEC filing: 09 Apr 2025
Next SEC filing: 09 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Madelyn Zeylikman, Attorney-in-Fact

Key filing fact

Sanj K. Patel filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 05 May 2025.

Key facts

This page summarizes Sanj K. Patel's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 05 May 2025, 16:49.

Change

Previous filing in this sequence was filed on 09 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001532218 Primary reporting owner

Patel Sanj K

Relationship: CHAIRMAN & CEO, Director
Address: 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Signature date: 05 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Performance Share Unit

Award

Transaction value: $0
Shares: +7,987
Change %
Price: $0.000000
Shares after: 7,987
Date: 01 May 2025
Ownership: Direct
Underlying class: Class A Ordinary Share
Underlying amount: 7,987
Exercise price
Footnotes: F1, F2, F3

KNSA transaction Derivative

Performance Share Unit

Award

Transaction value: $0
Shares: +8,386
Change %
Price: $0.000000
Shares after: 8,386
Date: 01 May 2025
Ownership: Direct
Underlying class: Class A Ordinary Share
Underlying amount: 8,386
Exercise price
Footnotes: F1, F2, F4

KNSA transaction Derivative

Performance Share Option

Award

Transaction value: $0
Shares: +12,910
Change %
Price: $0.000000
Shares after: 12,910
Date: 01 May 2025
Ownership: Direct
Underlying class: Class A Ordinary Share
Underlying amount: 12,910
Exercise price: $27.74
Footnotes: F2, F5

KNSA transaction Derivative

Performance Share Option

Award

Transaction value: $0
Shares: +13,328
Change %: +103%
Price: $0.000000
Shares after: 26,238
Date: 01 May 2025
Ownership: Direct
Underlying class: Class A Ordinary Share
Underlying amount: 13,328
Exercise price: $27.74
Footnotes: F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

Footnote F2

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

Footnote F3

The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F4

The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F5

The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

Footnote F6

The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.